Replies to post #20193 on Omni Health Inc (OMHE)

[Master-of-Disaster]

Why did you leave this part out?

“By employing an FDA regulations-savvy, ‘fast-track’ pipeline strategy, Omni Health will quickly be in a position to partner our new drug for late-phase development,” said Omni Health’s CEO, Andrey Soloviev. “Our projections set this target date at roughly three years out. It will be a strong competitor in a lucrative medicinal niche populated by a limited number of pain management products at exponentially higher valuations. Peer analysis shows these valuations to be in the range of $100 Million to $140 Million.”

By the time 3 years happens, Big Pharma will have stepped in to take over.